328 related articles for article (PubMed ID: 9721036)
21. 2-Arachidonoylglycerol and the cannabinoid receptors.
Sugiura T; Waku K
Chem Phys Lipids; 2000 Nov; 108(1-2):89-106. PubMed ID: 11106784
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid receptors and their endogenous ligands.
Sugiura T; Waku K
J Biochem; 2002 Jul; 132(1):7-12. PubMed ID: 12097154
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
24. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
25. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
[TBL] [Abstract][Full Text] [Related]
26. Control of pain initiation by endogenous cannabinoids.
Calignano A; La Rana G; Giuffrida A; Piomelli D
Nature; 1998 Jul; 394(6690):277-81. PubMed ID: 9685157
[TBL] [Abstract][Full Text] [Related]
27. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors.
Paria BC; Ma W; Andrenyak DM; Schmid PC; Schmid HH; Moody DE; Deng H; Makriyannis A; Dey SK
Biol Reprod; 1998 Jun; 58(6):1490-5. PubMed ID: 9623610
[TBL] [Abstract][Full Text] [Related]
28. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
29. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
30. Presence and regulation of the endocannabinoid system in human dendritic cells.
Matias I; Pochard P; Orlando P; Salzet M; Pestel J; Di Marzo V
Eur J Biochem; 2002 Aug; 269(15):3771-8. PubMed ID: 12153574
[TBL] [Abstract][Full Text] [Related]
31. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.
Shoemaker JL; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Nov; 315(2):828-38. PubMed ID: 16081674
[TBL] [Abstract][Full Text] [Related]
32. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
33. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
34. Endogenous cannabinoid signaling.
Piomelli D; Beltramo M; Giuffrida A; Stella N
Neurobiol Dis; 1998 Dec; 5(6 Pt B):462-73. PubMed ID: 9974178
[No Abstract] [Full Text] [Related]
35. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function.
Bisogno T; Berrendero F; Ambrosino G; Cebeira M; Ramos JA; Fernandez-Ruiz JJ; Di Marzo V
Biochem Biophys Res Commun; 1999 Mar; 256(2):377-80. PubMed ID: 10079192
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
37. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
[TBL] [Abstract][Full Text] [Related]
39. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
40. Where's my entourage? The curious case of 2-oleoylglycerol, 2-linolenoylglycerol, and 2-palmitoylglycerol.
Murataeva N; Dhopeshwarkar A; Yin D; Mitjavila J; Bradshaw H; Straiker A; Mackie K
Pharmacol Res; 2016 Aug; 110():173-180. PubMed ID: 27117667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
